Equity Securities (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
12 Months Ended |
|
|
|
|
|
Dec. 29, 2025 |
Nov. 01, 2025 |
Aug. 01, 2025 |
Mar. 31, 2025 |
Mar. 27, 2025 |
Jan. 31, 2025 |
Jan. 23, 2025 |
Jan. 21, 2025 |
Dec. 31, 2024 |
Sep. 17, 2024 |
May 31, 2024 |
May 21, 2024 |
May 16, 2024 |
Nov. 30, 2025 |
Jul. 31, 2024 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 30, 2025 |
Sep. 16, 2024 |
May 17, 2024 |
Nov. 30, 2023 |
May 26, 2023 |
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,424,617
|
|
|
|
|
|
|
| Common stock issuable upon exercise of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,105,295
|
|
|
|
|
|
|
| Remained shares amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,254,721
|
$ 3,081,352
|
|
|
|
|
|
| Proceeds from exercise of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
977
|
1,109
|
|
|
|
|
|
| Offering expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,495
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
506,822
|
|
|
|
|
|
|
5,424,617
|
506,822
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 12,167,852
|
$ 6,886,102
|
|
|
|
|
|
| Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
10,000,000
|
|
|
|
|
|
|
10,000,000
|
10,000,000
|
|
|
|
|
|
| Preferred stock, par value |
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
|
|
|
|
$ 0.0001
|
$ 0.0001
|
|
|
|
|
|
| Preferred stock, shares issue |
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
(0)
|
0
|
|
|
|
|
|
| Preferred stock, shares outstanding |
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
(0)
|
0
|
|
|
|
|
|
| Share price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.32
|
|
|
|
|
|
|
| Intrinsic value of warrants outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,200,000
|
|
|
|
|
|
|
| Reverse stock split description |
|
|
the Company effected the reverse
split of its shares of Common Stock at a ratio of 1-for-10, as approved by the Company’s board of directors (the “2025 Reverse
Stock Split”).
|
|
|
|
one-for-10 reverse stock split
|
|
|
|
|
|
the Company effected the reverse split
of its shares of Common Stock at a ratio of 1-for-15, as approved by the Company’s board of directors.
|
|
|
1-for-10 reverse stock split
|
|
|
|
|
|
|
| December 2025 PIPE [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant gross proceeds |
$ 4,100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| March 2025 Inducement Letter Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 15.80
|
$ 49.10
|
|
|
| Proceeds from exercise of warrants |
|
|
|
|
$ 5,700,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Legal fees |
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| May 2024 Inducement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering expenses |
|
|
|
|
|
|
|
|
|
|
|
$ 400,000
|
|
|
|
|
|
|
|
|
|
|
| Pre-Funded Warrants [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
$ 0.01
|
|
|
|
|
|
|
$ 0.001
|
$ 0.01
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
90,500
|
|
|
|
|
|
|
537,750
|
90,500
|
|
|
|
|
|
| December 2025 PIPE Placement Agents Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
141,544
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
$ 2.55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
$ 200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected term |
5 years 4 months 24 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
134.90%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk free interest rate |
3.67%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dividend yield |
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| New Series A Warrant [Member] | March 2025 Inducement Letter Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant gross proceeds |
|
|
|
|
$ 6,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
498,080
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant [Member] | March 2025 Inducement Letter Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
483,447
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
$ 12.84
|
$ 12.84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from exercise of warrants |
|
|
|
$ 5,700,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity issuance costs |
|
|
|
$ 4,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant [Member] | May 2024 Inducement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
|
|
|
51,633
|
51,633
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
|
$ 51.60
|
$ 51.60
|
|
|
|
|
|
|
|
|
$ 97.67
|
$ 324.00
|
| Proceeds from exercise of warrants |
|
|
|
|
|
|
|
|
|
|
$ 2,300,000
|
$ 2,300,000
|
|
|
|
|
|
|
|
|
|
|
| Equity issuance costs |
|
|
|
|
|
|
|
|
|
|
$ 1,500,000
|
|
|
|
|
|
|
|
|
|
|
|
| New Series B Warrant [Member] | March 2025 Inducement Letter Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
468,813
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| March 2025 Financial Advisor Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
33,840
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
$ 16.05
|
|
|
|
|
|
|
|
|
|
|
$ 16.05
|
|
|
|
|
|
|
| Fair value |
|
|
|
|
$ 400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected term |
|
|
|
|
5 years 3 months 18 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
143.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk free interest rate |
|
|
|
|
3.98%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dividend yield |
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33,840
|
|
|
|
|
|
|
| January 2025 PIPE Placement Agent Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
14,053
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
$ 15.88
|
|
|
|
|
|
|
|
$ 15.88
|
|
|
|
|
|
|
| Fair value |
|
|
|
|
|
|
|
$ 200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected term |
|
|
|
|
|
|
|
5 years 4 months 24 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
145.70%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk free interest rate |
|
|
|
|
|
|
|
4.45%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dividend yield |
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,053
|
|
|
|
|
|
|
| September 2024 PIPE Placement Agent Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
|
|
13,386
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
$ 22.88
|
|
|
|
|
|
$ 22.88
|
|
|
|
|
|
|
| Aggregate purchase price |
|
|
|
|
|
|
|
|
|
$ 300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected term |
|
|
|
|
|
|
|
|
|
5 years 6 months
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
149.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk free interest rate |
|
|
|
|
|
|
|
|
|
3.44%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dividend yield |
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
13,386
|
|
|
|
|
|
|
13,386
|
13,386
|
|
|
|
|
|
| May 2024 Series A Common Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 49.10
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
60,117
|
|
|
|
|
|
|
2,334
|
60,117
|
|
|
|
|
|
| May 2024 Series A Common Warrants [Member] | May 2024 Inducement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
|
|
|
60,117
|
60,117
|
|
|
|
|
|
|
|
|
|
|
| May 2024 Series B Common Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 49.10
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
43,149
|
|
|
|
|
|
|
|
43,149
|
|
|
|
|
|
| May 2024 Series B Common Warrants [Member] | May 2024 Inducement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
|
|
|
43,149
|
43,149
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
|
$ 49.10
|
|
|
|
|
|
|
|
|
|
|
|
| May 2023 Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
|
|
|
|
3,613
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
|
|
$ 64.50
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
| Expected term |
|
|
|
|
|
|
|
|
|
|
|
5 years 6 months
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
141.60%
|
|
|
|
|
|
|
|
|
|
|
| Risk free interest rate |
|
|
|
|
|
|
|
|
|
|
|
4.43%
|
|
|
|
|
|
|
|
|
|
|
| Dividend yield |
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
| March 2025 Warrant Inducement Series A Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 12.84
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
498,080
|
|
|
|
|
|
|
| March 2025 Warrant Inducement Series A Warrants [Member] | March 2025 Inducement Letter Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
498,080
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| March 2025 Warrant Inducement Series B Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 12.84
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
468,813
|
|
|
|
|
|
|
| March 2025 Warrant Inducement Series B Warrants [Member] | March 2025 Inducement Letter Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
468,813
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
$ 12.84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| January 2025 PIPE Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
$ 12.70
|
|
|
|
|
|
|
|
|
$ 12.70
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
120,734
|
|
|
|
|
|
|
|
|
80,051
|
|
|
|
|
|
|
| January 2025 PIPE Repriced Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.04
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
120,734
|
|
|
|
|
|
|
| Equity issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
193,539
|
100,756
|
|
|
|
|
|
| Remained shares amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 19
|
|
|
|
|
|
|
| Common Stock [Member] | March 2025 Inducement Letter Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
483,447
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 PIPE [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold |
1,470,588
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
537,750
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net cash proceeds |
$ 3,800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 PIPE [Member] | Company Insiders [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate purchase price |
$ 1,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 PIPE [Member] | Pre-Funded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
537,750
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 PIPE [Member] | Series C Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
2,022,062
|
|
|
|
|
|
|
2,022,062
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 PIPE [Member] | Series D Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
2,022,062
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issuable upon exercise of warrants |
2,022,062
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 PIPE [Member] | PIPE Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
$ 2.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 PIPE [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold |
1,484,312
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 PIPE [Member] | Common Stock [Member] | Company Insiders [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold |
735,294
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ATM Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,400,000
|
|
|
|
|
|
| ATM Agreement [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,800,000
|
|
|
|
|
|
|
|
|
| Fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 15,000
|
|
|
$ 1,700,000
|
|
|
|
|
|
| Fixed commission rate on gross sales price of common stock |
|
3.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00%
|
|
|
|
|
|
| Number of shares sold |
|
|
|
|
|
|
|
|
|
|
|
|
|
149,341
|
|
|
55,001
|
|
|
|
|
|
| Gross proceeds from offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 400,000
|
|
|
|
|
|
|
|
|
| Remained shares amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,400,000
|
|
|
|
|
|
|
|
|
| Net proceeds from offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 126,000
|
|
|
|
|
|
| January 2025 PIPE [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net cash proceeds |
|
|
|
|
|
|
|
$ 2,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering expenses |
|
|
|
|
|
|
|
300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| January 2025 PIPE [Member] | Company Insiders [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate purchase price |
|
|
|
|
|
$ 1,550,000
|
|
$ 1,550,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| January 2025 PIPE [Member] | Pre-Funded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
7,246
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
| January 2025 PIPE [Member] | PIPE Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
200,785
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
$ 12.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issuable upon exercise of warrants |
|
|
|
|
|
|
|
200,785
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| January 2025 PIPE [Member] | PIPE Warrants [Member] | Company Insiders [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
122,047
|
|
122,047
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| January 2025 PIPE [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold |
|
|
|
|
|
|
|
193,539
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| January 2025 PIPE [Member] | Common Stock [Member] | Company Insiders [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold |
|
|
|
|
|
122,047
|
|
122,047
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| September 2024 PIPE [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net cash proceeds |
|
|
|
|
|
|
|
|
|
$ 3,100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering expenses |
|
|
|
|
|
|
|
|
|
$ 400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| September 2024 PIPE [Member] | Pre-Funded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
|
|
191,256
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding, shares |
|
|
|
|
|
|
|
|
90,500
|
|
|
|
|
|
|
|
90,500
|
0
|
|
|
|
|
| Warrants exercised |
|
|
|
|
|
|
|
|
100,756
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| September 2024 PIPE [Member] | PIPE Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price |
|
|
|
|
|
|
|
|
|
$ 15.80
|
|
|
|
|
|
|
|
|
|
|
|
|
| September 2024 PIPE [Member] | Series A Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
|
|
191,256
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issuable upon exercise of warrants |
|
|
|
|
|
|
|
|
|
191,256
|
|
|
|
|
|
|
|
|
|
|
|
|
| September 2024 PIPE [Member] | Series B Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
|
|
|
|
|
|
|
191,256
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issuable upon exercise of warrants |
|
|
|
|
|
|
|
|
|
191,256
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,500,000
|
|
|
|
|
|
|
|
| September 2024 PIPE [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares sold |
|
|
|
|
|
|
|
|
|
191,256
|
|
|
|
|
|
|
|
|
|
|
|
|
| May 2024 Inducement [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,700,000
|
|
|
|
|
|
|
|